However, treatment with EGFR TKIs has shown limited success in glioblastoma compared to lung cancer due to changed kinetics of inhibitor binding or the reduced sensitivity of EGFRvIII (Nishikawa et al., 2004; Bonavia et al., 2012; Vivanco et al., 2012). The gene discussed is EGFR; the disease is glioblastoma.